Hansa Biopharma plans restructuring

Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company is initiating additional preclinical studies within its influenza program, with a focus on pandemic avian influenza.

At Elekta's Strategic Update for investors the company announced that, as a consequence of the company’s new operating model, it is reducing the number of employees by 450.

Nanologica has acquired Ardena Södertälje AB, the API CDMO in Södertälje, from Ardena Sweden in an all‑share deal valued at approximately SEK 8.6 million.

Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea 2mg, which is approved for marketing in the European Economic Area, United Kingdom and Japan.

BioArctic’s partner Eisai has announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the US Food and Drug Administration (FDA).